ABVC BioPharma, Inc.
ABVC · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $70,700 | $38,598 | $15,866 | $7,790 |
| - Cash | $192 | $388 | $152 | $248 |
| + Debt | $1,391 | $1,585 | $2,170 | $2,431 |
| Enterprise Value | $71,899 | $39,795 | $17,884 | $9,973 |
| Revenue | $796 | $0 | $0 | $2 |
| % Growth | – | – | -100% | – |
| Gross Profit | $796 | $0 | $0 | $2 |
| % Margin | 100% | – | – | 100% |
| EBITDA | -$1,281 | -$2,099 | -$607 | -$30 |
| % Margin | -161% | – | – | -1,530.5% |
| Net Income | -$1,247 | -$2,257 | -$842 | $229 |
| % Margin | -156.6% | – | – | 11,663.5% |
| EPS Diluted | -0.054 | -0.13 | -0.06 | 0.017 |
| % Growth | 58.8% | -116.7% | -448.8% | – |
| Operating Cash Flow | -$133 | -$894 | -$540 | -$494 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$133 | -$894 | -$540 | -$494 |